



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/28678/2018

## European Medicines Agency decision

P/0023/2018

of 30 January 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]- $\alpha,\alpha$ ,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976) (EMEA-002109-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0023/2018

of 30 January 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]- $\alpha,\alpha$ ,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976) (EMA-002109-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Gilead Sciences International Ltd. on 10 May 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 December 2017, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]- $\alpha,\alpha,5$ -trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976), film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]- $\alpha,\alpha,5$ -trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976), film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]- $\alpha,\alpha,5$ -trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976), film-coated tablet, age-appropriate oral solid dosage form, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to Gilead Sciences International Ltd., Flowers Building, Granta Park, Abingdon, CB21 6GT - Cambridge, United Kingdom.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/645186/2017

London, 15 December 2017

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002109-PIP01-16

### Scope of the application

#### Active substance(s):

1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]- $\alpha,\alpha,5$ -trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976)

#### Condition(s):

Treatment of non-alcoholic steatohepatitis (NASH)

#### Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral solid dosage form

#### Route(s) of administration:

Oral use

#### Name/corporate name of the PIP applicant:

Gilead Sciences International Ltd.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Ltd. submitted for agreement to the European Medicines Agency on 10 May 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 20 June 2017.

Supplementary information was provided by the applicant on 21 September 2017. The applicant proposed modifications to the paediatric investigation plan.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

## 1.1. Condition:

Treatment of non-alcoholic steatohepatitis (NASH)

The waiver applies to:

- the paediatric population from birth to less than 8 years;
- film-coated tablet, age-appropriate oral solid dosage form; oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

# 2. Paediatric investigation plan

## 2.1. Condition:

Treatment of non-alcoholic steatohepatitis (NASH)

### 2.1.1. Indication(s) targeted by the PIP

Treatment of non-alcoholic steatohepatitis (NASH) with moderate to severe fibrosis (F2-F4) in paediatric subjects, 8 to less than 18 years of age

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 8 to less than 18 years of age

### 2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral solid dosage form

### 2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	<b>Study 1</b> Development of a reduced dose-strength GS-0976 tablet (less than 5 mg)
Non-clinical studies	0	Not applicable.
Clinical studies	1	<b>Study 2</b> (GS-US-426-4381)

		Randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of GS-0976 in paediatric subjects aged 8 to < 18 years with non-alcoholic steatohepatitis (NASH) and moderate to severe fibrosis (F2-F4).
Extrapolation, modelling and simulation studies	1	<b>Study 3</b> Modelling and simulation study supporting GS-0976 paediatric dose selection
Other studies	0	Not applicable.
Other measures	0	Not applicable.

### 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By May 2032
Deferral for one or more measures contained in the paediatric investigation plan:	Yes